Four notes:
1. Bioventus posted second quarter net sales of $109.8 million, an 89.3 percent year-over-year increase.
2. The company posted a net loss of $10.8 million, an 80.3 percent increase.
3. Revenue from its pain treatments and joint preservation business was $56.7 million, a 96.4 percent increase. Preservation and restorative therapies revenue increased 80.9 percent with $32.6 million. Bone graft substitutes revenue was $20.6 million, an 84.3 percent increase.
4. Bioventus expects to see net sales of $405 million to $415 million this year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
